In AML, the frequency of P53 mutations ranges from 4 to 15% (61) and it is, therefore, very low if compared with other types of cancer, such as the high-grade serous carcinoma of the ovary, where P53 mutation rates are close to 100%. This evidence concerns the gene TP53 and cancer.